Expertise

Ovodan Biotech has a well-established network within academia. Therefore, our activities also include projects where we develop antibodies for research projects. The projects allow us to explore new areas of application and utilize new technologies in collaboration with true experts. Among others, the projects include diagnostics within IBD and COVID-19.

IBD - Inflammatory Bowel Disease

IBD – inflammatory bowel disease – covers diseases as Ulcerative colitis and Crohn’s disease. More than 6 million patients are today diagnosed with IBD. The symptoms involve severe diarrhea, abdominal pain, fatigue and weight loss and it is likely to have periods of active illness followed by periods of remission.

Consequently, patients are supported by monitoring the level of the inflammation biomarker Calprotectin, a highly conserved mammal protein present at local inflammation sites. In the case of IBD also in fecal samples.

At Ovodan Biotech we have developed chicken polyclonal antibodies toward Calprotectin (MRP-14). As host chickens are the perfect choice since Calprotectin are considered highly conserved within mammal strains. Furthermore, the anti-MRP-14 IgY does not cross react with rheumatoid factors or mammalian Fc receptors.

We are closely following the research within this area to support patients and physicians to develop better and more specific diagnostic tools. And we are always open to dialogues about projects where we can contribute with our experience.

COVID-19

The pandemic virus SARS-CoV-2 requires no further presentation. Vaccines are under development, so are different treatments and diagnostics tests has been on the market for months. But as the pandemic spreads around the world and cities are locked down to controlled breakouts, it is obvious the virus is here to stay for a while.

At Ovodan Biotech we are convinced that a faster, more specific, and reliable rapid test is needed on the market. And we strive to deliver the most potent antibodies for this purpose. Therefore, we have initiated immunization of hens and alpacas during the early spring and are close to launch of the first polyclonal chicken antibodies for testing.

We are still open to a collaboration with assay developers that share our ambition. Please contact us for a dialogue.